Traders Buying Dendreon (DNDN) Shares Ahead of Provenge Coverage Determination
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 13 | New: 29
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 13 | New: 29
Join SI Premium – FREE
Shares of Dendreon (Nasdaq: DNDN) are currently up nearly 4 percent following some bullish comments on the company's Provenge from analysts at both JPMorgan and RBC Capital.
A JPMorgan conference call to discuss the Dendreon product has just begun (11am ET).
JPMorgan believes National Coverage Analysis will support Provenge based on current labeling as the drug has shown overall survival benefit in castrate resistant prostate cancer. The firm says this decision is expected on March 30th.
Elsewhere on the Street, RBC suggests Dendreon's Provenge could become at least a $1 billion drug. The firm sees a 15-20% chance that National Coverage Analysis will not offer a coverage determination at this time.
JPMorgan maintains an Overweight rating and $66 price target on Dendreon shares, while RBC maintains an Outperform and $50 price target.
To track all the market-moving analyst action on shares of Dendreon, visit our Analyst Ratings page.
A JPMorgan conference call to discuss the Dendreon product has just begun (11am ET).
JPMorgan believes National Coverage Analysis will support Provenge based on current labeling as the drug has shown overall survival benefit in castrate resistant prostate cancer. The firm says this decision is expected on March 30th.
Elsewhere on the Street, RBC suggests Dendreon's Provenge could become at least a $1 billion drug. The firm sees a 15-20% chance that National Coverage Analysis will not offer a coverage determination at this time.
JPMorgan maintains an Overweight rating and $66 price target on Dendreon shares, while RBC maintains an Outperform and $50 price target.
To track all the market-moving analyst action on shares of Dendreon, visit our Analyst Ratings page.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bending Spoons to acquire Miro at $1.4B value
- RBC Capital Starts Shake Shack (SHAK) at Outperform
- Canaccord Starts 908 Devices Inc. (MASS) at Buy
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
JPMorgan, RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
